Jeraygo

Aprocitentan, the active ingredient in Jeraygo, is an endothelin receptor antagonist presented as an oral tablet for systemic use. It is indicated for the management of resistant hypertension, a condition where blood pressure remains elevated despite the use of multiple antihypertensive agents, and is prescribed for adult patients requiring additional blood pressure control.

GNH USA supplies Jeraygo as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets with a focus on quality and regulatory conformity.

Aprocitentan, marketed as Jeraygo, is used in the endothelin pathway to manage resistant hypertension.

Resistant hypertension: lowers blood pressure in patients whose hypertension is uncontrolled despite use of at least three antihypertensive agents, including a diuretic.

Aprocitentan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Dizziness - Peripheral edema - Fatigue

Serious or Rare Side Effects: - Hepatic enzyme elevation - Significant hypotension - Anemia - Renal impairment - Angioedema - Pulmonary edema

When prescribing Aprocitentan, several precautionary measures should be observed. - Blood pressure monitoring: measure regularly to detect excessive hypotension. - Renal function: assess baseline and periodic creatinine levels. - Hepatic function: monitor liver enzymes during therapy. - Electrolytes: check potassium and sodium concentrations. - Pregnancy and lactation: avoid use due to unknown safety. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Aprocitentan can interact with other medicines, requiring attention to the nature of each interaction.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Aprocitentan exposure. - Potent CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Co‑administration with other endothelin antagonists: additive vasodilatory effect leading to hypotension.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may increase risk of renal impairment. - Diuretics: may potentiate hypotensive effect. - ACE inhibitors or ARBs: monitor for additive blood‑pressure lowering.